
Phu Hoang Nguyen
Examiner (ID: 14741, Phone: (571)272-5931 , Office: P/1747 )
| Most Active Art Unit | 1747 |
| Art Unit(s) | 1731, 1747, 1791 |
| Total Applications | 942 |
| Issued Applications | 511 |
| Pending Applications | 112 |
| Abandoned Applications | 343 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18169112
[patent_doc_number] => 20230035723
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-02
[patent_title] => Treatment of Pancreatic Cancer
[patent_app_type] => utility
[patent_app_number] => 17/652409
[patent_app_country] => US
[patent_app_date] => 2022-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11364
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17652409
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/652409 | Treatment of Pancreatic Cancer | Feb 23, 2022 | Abandoned |
Array
(
[id] => 18107899
[patent_doc_number] => 20230000779
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => ROOM TEMPERATURE STABLE ORAL CALCITONIN FORMULATION
[patent_app_type] => utility
[patent_app_number] => 17/675643
[patent_app_country] => US
[patent_app_date] => 2022-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41149
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17675643
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/675643 | Room temperature stable oral calcitonin formulation | Feb 17, 2022 | Issued |
Array
(
[id] => 18565559
[patent_doc_number] => 20230255886
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => SELF-EMULSIONABLE MINERAL OIL AS A VEHICLE IN VACCINES FOR POULTRY
[patent_app_type] => utility
[patent_app_number] => 17/673315
[patent_app_country] => US
[patent_app_date] => 2022-02-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5776
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673315
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/673315 | Self-emulsionable mineral oil as a vehicle in vaccines for poultry | Feb 15, 2022 | Issued |
Array
(
[id] => 19142515
[patent_doc_number] => 20240141357
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-02
[patent_title] => METHODS AND COMPOSITIONS FOR MODULATING PLASMINOGEN
[patent_app_type] => utility
[patent_app_number] => 18/546414
[patent_app_country] => US
[patent_app_date] => 2022-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7780
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18546414
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/546414 | METHODS AND COMPOSITIONS FOR MODULATING PLASMINOGEN | Feb 13, 2022 | Pending |
Array
(
[id] => 20231385
[patent_doc_number] => 20250288704
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-09-18
[patent_title] => CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/276802
[patent_app_country] => US
[patent_app_date] => 2022-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27321
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 162
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18276802
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/276802 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Feb 13, 2022 | Pending |
Array
(
[id] => 17821426
[patent_doc_number] => 11426348
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-30
[patent_title] => Compositions of bupivacaine multivesicular liposomes
[patent_app_type] => utility
[patent_app_number] => 17/590636
[patent_app_country] => US
[patent_app_date] => 2022-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 6
[patent_no_of_words] => 11007
[patent_no_of_claims] => 58
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17590636
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/590636 | Compositions of bupivacaine multivesicular liposomes | Jan 31, 2022 | Issued |
Array
(
[id] => 17593464
[patent_doc_number] => 20220143037
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/586228
[patent_app_country] => US
[patent_app_date] => 2022-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21490
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17586228
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/586228 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS | Jan 26, 2022 | Abandoned |
Array
(
[id] => 19273295
[patent_doc_number] => 12023402
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-02
[patent_title] => Oral care compositions
[patent_app_type] => utility
[patent_app_number] => 17/581189
[patent_app_country] => US
[patent_app_date] => 2022-01-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8020
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17581189
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/581189 | Oral care compositions | Jan 20, 2022 | Issued |
Array
(
[id] => 17702871
[patent_doc_number] => 20220202877
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => COMPOSITION FOR PREVENTION OR TREATMENT OF OCULAR DISEASES COMPRISING EXTRACELLULAR VESICLES DERIVED FROM MICROCOCCUS LUTEUS
[patent_app_type] => utility
[patent_app_number] => 17/646140
[patent_app_country] => US
[patent_app_date] => 2021-12-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10281
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17646140
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/646140 | Composition for prevention or treatment of ocular diseases comprising extracellular vesicles derived from | Dec 26, 2021 | Issued |
Array
(
[id] => 19018815
[patent_doc_number] => 20240074986
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => Methods of Enhancing Non-Viral Gene Therapy
[patent_app_type] => utility
[patent_app_number] => 18/258981
[patent_app_country] => US
[patent_app_date] => 2021-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23365
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18258981
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/258981 | Methods of Enhancing Non-Viral Gene Therapy | Dec 21, 2021 | Pending |
Array
(
[id] => 19431018
[patent_doc_number] => 20240299516
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => MULTILAMELLAR RNA NANOPARTICLE VACCINE AGAINST CANCER
[patent_app_type] => utility
[patent_app_number] => 18/268725
[patent_app_country] => US
[patent_app_date] => 2021-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17667
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18268725
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/268725 | MULTILAMELLAR RNA NANOPARTICLE VACCINE AGAINST CANCER | Dec 19, 2021 | Pending |
Array
(
[id] => 18953739
[patent_doc_number] => 20240042066
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => FIBROBLAST ACTIVATION PROTEIN INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/258379
[patent_app_country] => US
[patent_app_date] => 2021-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9253
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18258379
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/258379 | FIBROBLAST ACTIVATION PROTEIN INHIBITOR | Dec 19, 2021 | Pending |
Array
(
[id] => 19641270
[patent_doc_number] => 20240415790
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-19
[patent_title] => A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL DISC HERNIATION
[patent_app_type] => utility
[patent_app_number] => 18/267648
[patent_app_country] => US
[patent_app_date] => 2021-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12533
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18267648
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/267648 | A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL DISC HERNIATION | Dec 16, 2021 | Pending |
Array
(
[id] => 17790305
[patent_doc_number] => 20220249396
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY
[patent_app_type] => utility
[patent_app_number] => 17/552487
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3314
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17552487
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/552487 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | Dec 15, 2021 | Abandoned |
Array
(
[id] => 18953442
[patent_doc_number] => 20240041769
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-08
[patent_title] => COMPOSITIONS AND METHODS FOR DELIVERY OF ANTICANCER AGENTS WITH IMPROVED THERAPEUTIC INDEX
[patent_app_type] => utility
[patent_app_number] => 18/257501
[patent_app_country] => US
[patent_app_date] => 2021-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25889
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257501
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/257501 | COMPOSITIONS AND METHODS FOR DELIVERY OF ANTICANCER AGENTS WITH IMPROVED THERAPEUTIC INDEX | Dec 13, 2021 | Pending |
Array
(
[id] => 17685647
[patent_doc_number] => 20220192939
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => Composition For The Remineralization Of Teeth
[patent_app_type] => utility
[patent_app_number] => 17/549959
[patent_app_country] => US
[patent_app_date] => 2021-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5488
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17549959
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/549959 | Composition For The Remineralization Of Teeth | Dec 13, 2021 | Pending |
Array
(
[id] => 18860073
[patent_doc_number] => 20230414507
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => CD1D-LIGAND-COMPOUND-CONTAINING LIPOSOME PREPARATION HAVING IMPROVED PHARMACOKINETICS
[patent_app_type] => utility
[patent_app_number] => 18/255158
[patent_app_country] => US
[patent_app_date] => 2021-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255158
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/255158 | CD1D-LIGAND-COMPOUND-CONTAINING LIPOSOME PREPARATION HAVING IMPROVED PHARMACOKINETICS | Dec 1, 2021 | Pending |
Array
(
[id] => 19096513
[patent_doc_number] => 20240115740
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => PRECISE LABELING OF PROTEIN SCAFFOLDS WITH CARGO FOR USE IN BIOMEDICAL APPLICATIONS
[patent_app_type] => utility
[patent_app_number] => 18/254851
[patent_app_country] => US
[patent_app_date] => 2021-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11986
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18254851
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/254851 | PRECISE LABELING OF PROTEIN SCAFFOLDS WITH CARGO FOR USE IN BIOMEDICAL APPLICATIONS | Nov 29, 2021 | Pending |
Array
(
[id] => 18893846
[patent_doc_number] => 20240009331
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 18/039542
[patent_app_country] => US
[patent_app_date] => 2021-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3718
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039542
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/039542 | UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR TARGETED RADIOLABELED PEPTIDE CONJUGATES | Nov 25, 2021 | Pending |
Array
(
[id] => 19570440
[patent_doc_number] => 20240374732
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES
[patent_app_type] => utility
[patent_app_number] => 18/254122
[patent_app_country] => US
[patent_app_date] => 2021-11-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13346
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18254122
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/254122 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | Nov 23, 2021 | Pending |